Search Results
Apr 28, 2026, 08:00 ET STUDY: CANCER PATIENTS EXPERIENCE LONGER SURVIVAL IN COMMUNITY ONCOLOGY SETTINGS
Network (FHRN) community oncology practice exceeded national benchmarks by eight months. Median survival for those with non-small cell lung cancer—the most common lung cancer—treated at FHRN community oncology practices exceeded national benchmarks by two months. Survival rates after one, three, and five
More news about: Community Oncology Alliance
Apr 28, 2026, 08:00 ET AbbVie Submits Application to FDA for Upadacitinib (RINVOQ®) for Adults and Adolescents with Severe Alopecia Areata
Lymphoma and other cancers, including skin cancers, can happen. Current or past smokers are at higher risk of certain cancers, including lymphoma and lung cancer. Follow your HCP's advice about having your skin checked for skin cancer during treatment with RINVOQ. Limit the amount of time you spend in
More news about: AbbVie
Apr 28, 2026, 07:00 ET Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes at the 2026 American Society of Gene and Cell Therapy Annual Meeting
candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), is being evaluated in two clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program
More news about: Genprex, Inc.
Apr 28, 2026, 04:07 ET Ivonescimab Receives Major Recommendations Across Multiple Therapies in the 2026 CSCO NSCLC Guideline
later-line settings in the officially updated 2026 Chinese Society of Clinical Oncology (CSCO) Guideline for the Diagnosis and Treatment of Non-Small Cell Lung Cancer (NSCLC). These strong recommendations further solidify ivonescimab's breakthrough clinical value and its position as a new standard of care (SOC),
More news about: Akeso, Inc.
Apr 27, 2026, 17:05 ET In HelloNation, Veterinary Expert Dr. Tracey Hutson of Boca Raton, FL, Highlights the Value of Annual Wellness Exams
effective.During each visit, veterinarians assess a wide range of physical indicators, including weight, coat condition, joint movement, and heart and lung sounds. These routine checks help build a baseline for pet health monitoring. According to the article, consistency is key; regular exams allow patterns
More news about: HelloNation
Apr 27, 2026, 11:00 ET DELFI Diagnostics Appoints Charles Newton to Board of Directors
blood, an approach known as fragmentomics, to help detect lung cancer with high sensitivity. FirstLook Lung, the first commercially available blood-based screening test for lung cancer in the United States, serves individuals eligible for lung cancer screening through a simple blood draw that integrates
More news about: DELFI Diagnostics
Apr 27, 2026, 10:24 ET In HelloNation, Radon Mitigation Expert Paul Nicholson Discusses Key Factors in Radon Mitigation Systems
foundation cracks and other openings, or simply pressurize through the foundation floor. Prolonged exposure to elevated radon levels has been linked to lung cancer, and is suspected in Leukemia and Lymphoma cases. Because radon cannot be detected without testing, homeowners must rely on proper measurement
More news about: HelloNation
Apr 27, 2026, 09:00 ET TytoCare Secures FDA De Novo for First AI-Powered Eardrum Analysis
TytoCare is enhancing its Smart Clinic Companion with new Smart Checkup capabilities, empowering patients with insights about their lung and ear exams, leveraging Tyto Insights™ Lung Suite and ENT Suite. The Smart Checkup is designed to support patients with deeper understanding and more informed decision-making,
More news about: TytoCare
Apr 27, 2026, 08:00 ET Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
to both NSCLC and CNS guidelines."ROS1+ NSCLC is a rare and aggressive form of lung cancer, accounting for approximately 2% of new NSCLC cases. The median age at diagnosis for patients with this type of lung cancer is approximately 50 years old, and the disease is more likely to occur in people
More news about: Nuvation Bio Inc.
Apr 27, 2026, 07:55 ET Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
(ensartinib), the company's novel therapy for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC).
More news about: EVERSANA
Apr 25, 2026, 03:05 ET Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation - IMMP
Independent Data Monitoring Committee (IDMC) for the TACTI-004 Phase III study evaluating eftilagimod alfa ('efti') in patients in 1(st) line non-small cell lung cancer has recommended the discontinuation of the trial following a planned interim futility analysis in accordance with the study protocol." In addition,
More news about: THE ROSEN LAW FIRM, P. A.
Apr 24, 2026, 08:40 ET Florida Cancer Specialists & Research Institute Advances Oncology Care Through Expert Collaboration and Innovative Exchange at Exclusive Event
Maria Regina Flores, MD – EGFR Mutation-Positive Non-Small Cell Lung Cancer
More news about: Florida Cancer Specialists & Research Institute
Apr 23, 2026, 09:04 ET Cipla Receives U.S. FDA Approval for First AB-Rated Generic of Ventolin® HFA
Limited, said: "This marks an important milestone for Cipla and reflects our strong scientific and regulatory capabilities in complex inhalation products. Lung health remains at the heart of all our offerings and follows a singular, distilled objective, to build a sustainable and differentiated portfolio for
More news about: Cipla USA Inc.
Apr 23, 2026, 09:00 ET Cumberland Pharmaceuticals Announces Strategic Transaction to Integrate Commercial Business with Apotex
with Duchenne muscular dystrophy ("DMD"). This rare, fatal genetic neuromuscular disease results in deterioration of the skeletal, heart and lung muscles. Interactions with the FDA are underway regarding the study results and remaining requirements for approval. The program has received Orphan
More news about: Cumberland Pharmaceuticals Inc.
Apr 23, 2026, 08:19 ET Zendure trình làng dòng SolarFlow Mix Series tại Châu Âu -- Ba hệ thống lưu trữ gia đình, một nền tảng, giảm tới 91% hóa đơn điện
ZendureZendure là đơn vị tiên phong toàn cầu trong lĩnh vực Hệ thống Quản lý Năng lượng Gia đình (HEMS) dạng cắm, với các trung tâm R&D và vận hành tại Thung lũng Silicon, Khu vực Vịnh Lớn, Nhật Bản và Đức. Sứ mệnh của Zendure là cung cấp năng lượng sạch đáng tin cậy và giá cả phải chăng cho các hộ gia đình trên
More news about: Zendure
Apr 23, 2026, 07:11 ET High Levels of Gut Bacterial Wall Toxin Shown to Trigger Lupus Nephritis
San Antonio, Betsy Barnes at the Feinstein Institutes for Medical Research in New York City, and Nicolas Gisch at the Research Center Borstel, Leibniz Lung Center, in Germany.About NYU Langone HealthNYU Langone Health is a fully integrated health system that consistently achieves the
More news about: NYU Langone Health System
Apr 23, 2026, 07:00 ET TransMedics to Provide Update on Ongoing Clinical Programs at the International Society of Heart and Lung Transplantation 2026 Annual Meeting
company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, is today providing an update on its ongoing clinical programs at the International Society of Heart and Lung Transplantation (ISHLT) 2026 Annual Meeting in Toronto, Canada. At the meeting,
More news about: TransMedics Group, Inc.
Apr 23, 2026, 07:00 ET Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two therapies approved to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering,
More news about: Insmed Incorporated
Apr 22, 2026, 23:37 ET AACR 2026 | Abbisko Therapeutics Showcases Six Research Advances Highlighting pan-KRAS, 4th Generation EGFR, and Synthetic Lethality Approaches
Inhibition Across KRAS MutationsKRAS mutations are highly prevalent across multiple cancers, including pancreatic (~90%), colorectal (~35%), and lung cancer (~25%). While several pan-KRAS inhibitors have entered clinical development, there remains a critical need for enhanced potency.In preclinical
More news about: Abbisko Therapeutics
Apr 22, 2026, 12:40 ET First Traveling Bedside PDA Closure Performed at Nicklaus Children's Hospital Fort Lauderdale NICU
of transporting a fragile babyEliminated risks associated with transporting fragile newbornsEarly intervention that allows improved lung recoveryA Minimally invasive technique that involves a small catheter to close the vessel without a chest incisionA small blood
More news about: Nicklaus Children's Health System
Apr 22, 2026, 11:40 ET Global Lung Cancer Therapeutics Market to Reach USD 142.3 Billion as Precision Medicine and Immunotherapy Redefine Oncology Care | Future Market Insights
https://www.futuremarketinsights.com/checkout/422Related ReportsLung Cancer Diagnostics Market: https://www.futuremarketinsights.com/reports/lung-cancer-diagnostics-marketLung Cancer Molecular Biomarker Market:
More news about: Future Market Insights
Apr 22, 2026, 11:01 ET Pulmonary Fibrosis Foundation Expands Leadership To Drive Scientific and Partnership Strategy
Network, which supports specialized interstitial lung disease centers across the country, and has overseen the PFF Registry, a key research resource for patients, families, caregivers and lung transplant recipients affected by pulmonary fibrosis and interstitial lung disease. Her own research uses qualitative
More news about: The Pulmonary Fibrosis Foundation
Apr 22, 2026, 08:45 ET Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy at the International Society for Cell & Gene Therapy 2026 Annual Meeting
breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms
More news about: Anixa Biosciences, Inc.
Apr 22, 2026, 07:00 ET Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting
monotherapy demonstrates greater anti-tumor activity than Dato-DXd (TROP-2 ADC approved in EGFR-mutant lung cancer) and izalontamab brengitecan (HER3-EGFR bispecific ADC in development for EGFR-mutant lung cancer). ATNM-400 also demonstrates greater anti-tumor activity than the EGFR-cMET bispecific antibody
More news about: Actinium Pharmaceuticals, Inc.
Apr 22, 2026, 07:00 ET Positive Clinical Data on Biomarkers in Patients Receiving Reqorsa® Gene Therapy To Be Released at the 2026 ASCO Annual Meeting
studies of predictive biomarkers in patients receiving its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of lung cancer.
More news about: Genprex, Inc.